Clinical Trial Results:
Assessment of Hepatic Glucose Production Following Repeated Glucagon Administration in Type 1 Diabetes Patients
Summary
|
|
EudraCT number |
2013-001407-36 |
Trial protocol |
AT |
Global end of trial date |
10 Apr 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
26 Mar 2021
|
First version publication date |
26 Mar 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
HEPPI
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Medical University of Graz
|
||
Sponsor organisation address |
Auenbruggerplatz 15, Graz, Austria, A-8036
|
||
Public contact |
Center for Medical Research (ZMF), Medical University of Graz; Dept. of Internal Medicine; Division of Endocrinology and
Diabetology, +43 31638572831, werner.regittnig@medunigraz.at
|
||
Scientific contact |
Center for Medical Research (ZMF), Medical University of Graz; Dept. of Internal Medicine; Division of Endocrinology and
Diabetology, +43 31638572831, werner.regittnig@medunigraz.at
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
31 Aug 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
10 Apr 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
10 Apr 2014
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the effect of repeated subcutaneous glucagon administration on the hepatic glucose production in type 1 diabetic patients under fed and fasted conditions.
|
||
Protection of trial subjects |
Number of intravenous catheters inserted as well as the number of blood samples drawn during the two study visits were minimised to minimise distress and pain.
|
||
Background therapy |
On the days before and after the two study visits, study subjects were either treated with multiple daily injections (MDI) of insulin or continuous subcutaneous insulin infusion (CSII). | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
06 May 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Austria: 9
|
||
Worldwide total number of subjects |
9
|
||
EEA total number of subjects |
9
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
9
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Patients were recruited from the diabetes out-patient clinic of the Medical University of Graz. Recruitment period lasted from May 2013 to April 2014. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
10 subjects were screened. They were of both sexes, in the age group of 18–64 years and diagnosed with type 1 diabetes. They had to have HbA1C values of <10%, and had to be treated with multiple daily injection of insulin or continuous subcutaneous insulin infusion. One patient was excluded due to a screening failure. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Overall Period
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
No
|
||||||||||||||||||
Arm title
|
Fasted Conditions | ||||||||||||||||||
Arm description |
In this arm, subjects were given three subcutaneous boluses of glucagon (1 mg) in the fasted state (i.e., 20 hours post-meal). The boluses of glucagon were separated by 180 minutes. To restore normoglycemia after each glucagon bolus, the subjects engaged in moderate-intensity exercise. | ||||||||||||||||||
Arm type |
crossover | ||||||||||||||||||
Investigational medicinal product name |
Glucagon
|
||||||||||||||||||
Investigational medicinal product code |
SUB02347MIG
|
||||||||||||||||||
Other name |
GlucaGen
|
||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for injection
|
||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||
Dosage and administration details |
3 x 1 mg
|
||||||||||||||||||
Arm title
|
Fed Conditions | ||||||||||||||||||
Arm description |
In this arm, subjects were given three subcutaneous boluses of glucagon (1 mg) in the fed state (i.e., 6 hours post-meal). The boluses of glucagon were separated by 180 minutes. To restore normoglycemia after each glucagon bolus, the subjects engaged in moderate-intensity exercise. | ||||||||||||||||||
Arm type |
crossover | ||||||||||||||||||
Investigational medicinal product name |
Glucagon
|
||||||||||||||||||
Investigational medicinal product code |
SUB02347MIG
|
||||||||||||||||||
Other name |
GlucaGen
|
||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for injection
|
||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||
Dosage and administration details |
3 x 1 mg
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall Period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Overall Population as this is a cross-over trial | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Fasted Conditions
|
||
Reporting group description |
In this arm, subjects were given three subcutaneous boluses of glucagon (1 mg) in the fasted state (i.e., 20 hours post-meal). The boluses of glucagon were separated by 180 minutes. To restore normoglycemia after each glucagon bolus, the subjects engaged in moderate-intensity exercise. | ||
Reporting group title |
Fed Conditions
|
||
Reporting group description |
In this arm, subjects were given three subcutaneous boluses of glucagon (1 mg) in the fed state (i.e., 6 hours post-meal). The boluses of glucagon were separated by 180 minutes. To restore normoglycemia after each glucagon bolus, the subjects engaged in moderate-intensity exercise. |
|
|||||||||||||
End point title |
AUC HGP - fasted vs. fed conditions | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Area under the hepatic glucose production curve (AUC HGP) from 0 to 90 minutes after the glucagon bolus injections.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
AUC HGP - fasted vs. fed conditions | ||||||||||||
Comparison groups |
Fasted Conditions v Fed Conditions
|
||||||||||||
Number of subjects included in analysis |
8
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.82 | ||||||||||||
Method |
2-sided paired t-test | ||||||||||||
Confidence interval |
|
|||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
from the onset of screening to the last patient last visit
|
||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.1
|
||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |